transmembrane protein 30C, pseudogeneGenealiases: []
Q-omics provides the consensus-scored TMEM30CP profile across patient tissues and cancer cell-line models. TMEM30CP expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TMEM30CP is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, TMEM30CP RNA expression shows 6,926 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where TMEM30CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM30CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM30CP survival associations across molecular data types. TMEM30CP RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM30CP RNA expression–survival associations across cancer types. High TMEM30CP expression shows unfavorable associations in KICH, ACC, DLBC, MESO and KIRC, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for TMEM30CP RNA expression.
This table summarizes TMEM30CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM30CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM30CP shows higher tumor expression in COAD, UCEC and PRAD. The COAD box plot shows higher TMEM30CP RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .027).
This table shows molecular features associated with TMEM30CP in patient tissues and cancer cell lines. In patient samples, TMEM30CP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
